The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 1, 2011, Pages 3-13

  Nichols, A I ^a   Richards, L S ^c   Behrle, J A ^b   Posener, J A ^a   McGrory, S B ^a   Paul, J ^a  

^a PFIZER INC   (United States)

^b CENTOCOR INC   (United States)

^c NONE

Author keywords

Anti depressants; Desvenlafaxine; Pharmacokinetics; Renal impairment

Indexed keywords

CREATININE; DESVENLAFAXINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; COUGHING; CREATININE CLEARANCE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; ECG ABNORMALITY; FEMALE; FEVER; GENERALIZED EDEMA; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; KIDNEY FUNCTION TEST; MAJOR DEPRESSION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PLASMA CONCENTRATION-TIME CURVE; QT PROLONGATION; RENAL REPLACEMENT THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TASTE DISORDER; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; CYCLOHEXANOLS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; STEREOISOMERISM;

EID: 78650842303     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP49003     Document Type: Article

References (11)

1. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000; 283: 3082-3088. (Pubitemid 30399718)
2. Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry. 2007; 9: 100-107.
3. Dell'Osso B, Nestadt G, Allen A, Hollander E. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. J Clin Psychiatry. 2006; 67: 600-610.
4. Silverstone PH. Qualitative review of SNRIs in anxiety. J Clin Psychiatry. 2004; 65 (Suppl): 19-28.
5. Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs. 2007; 67: 569-585.
6. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004; 110: 697-706.
7. Crone CC, Gabriel GM. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2004; 43: 361-394.
8. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006; 318: 657-665.
9. Howell SR, Husbands GE, Scatina JA, Sisenwine SF. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica. 1993; 23: 349-359.
10. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res. 1991; 23: 191-199.
11. Pristiq [package insert]. Wyeth Pharmaceutical, Collegeville, PA, 2008.